Active, not recruitingPhase 2NCT05601752
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
Studying Malignant epithelial tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- USWM CT, LLC
- Intervention
- Autologous genetically modified ADP-A2M4CD8 cells(genetic)
- Enrollment
- 66 enrolled
- Eligibility
- 18-75 years · FEMALE
- Timeline
- 2023 – 2026
Study locations (23)
- Honor Health, Scottsdale, Arizona, United States
- City of Hope, Duarte, California, United States
- Augusta University, Augusta, Georgia, United States
- Karmanos Cancer Institute, Detroit, Michigan, United States
- Rutgers Cancer Institute of NJ, New Brunswick, New Jersey, United States
- Cleveland Clinic Foundation, Cleveland, Ohio, United States
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
- Avera Cancer Institute, Sioux Falls, South Dakota, United States
- Swedish Cancer Institute, Seattle, Washington, United States
- University Health Network (Princess Margaret Cancer Center), Toronto, Ontario, Canada
- Institut de Cancerologie des Hospices Civils de Lyon, Pierre-Bénite, Lyon, France
- Centre Leon-Berard, Lyon, France
- Institut de Cancerologie de Strasbourg, Strasbourg, France
- Institut Gustave Roussy, Villejuif, France
- Vall d'Hebron Unversity Hospital, Barcelona, Spain
- +8 more locations on ClinicalTrials.gov
Collaborators
GOG Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05601752 on ClinicalTrials.govOther trials for Malignant epithelial tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07508306Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical MorbidityFaculty of Medicine of Tunis
- RECRUITINGPHASE1NCT07524322Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsRegor Pharmaceuticals Inc.
- RECRUITINGPHASE1NCT06366490Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian CancerPhotonPharma, Inc.
- RECRUITINGPHASE1NCT07402915Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube CancerAstraZeneca
- RECRUITINGPHASE2NCT07158021Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS TrialUniversity of Michigan Rogel Cancer Center
- RECRUITINGNANCT07280312Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal LesionsMayo Clinic
- RECRUITINGPHASE2NCT06971744Autophagy Maintenance (AUTOMAIN)Medical University of South Carolina
- RECRUITINGPHASE3NCT06963268Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II)Instituto de Investigacion Sanitaria La Fe